iDerazantinib; ARQ-087
Iinkcukacha zeMveliso
Iithegi zeMveliso
| Ubungakanani bePakethi | Ubukho | Ixabiso (USD) |
| 10mg | Ikhona evenkileni | 800 |
| 100mg | Ikhona evenkileni | 1200 |
| 500mg | Ikhona evenkileni | 1800 |
| Iisayizi ezininzi | Fumana iiQuotes | Fumana iiQuotes |
Igama leMchiza:
(6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine
Ikhowudi yoncumo:
COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1
Ikhowudi ye-InChi:
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24- 10-4-5-12-2 7(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H ,32,33,34)/t26-/m1/s1
Isitshixo se-InChi:
I-KPJDVVCDVBFRMU-AREMUKBSSA-N
Igama elingundoqo:
Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4
Ukunyibilika:Inyibilika kwi-DMSO
Ugcino:0 - 4°C ixesha elifutshane (iintsuku ukuya kwiiveki), okanye -20°C ixesha elide (iinyanga).
Inkcazo:
I-Derazantinib, eyaziwa ngokuba yi-ARQ-087, yi-inhibitor ye-bioavailable yomlomo ye-fibroblast growth factor receptor (FGFR) enomsebenzi we-antineoplastic. I-FGFR inhibitor ARQ 087 ibophelela kwaye inqande ngokunamandla umsebenzi we-FGFR subtypes 1, 2 kunye ne-3. Oku kunokubangela ukuvinjelwa kwe-FGFR-mediated transduction pathways, i-tumor cell proliferation, i-tumor angiogenesis kunye ne-tumor cell death kwi-FGFR-overexpressing cell tumor cells. . I-FGFR, i-receptor tyrosine kinase, ilawulwa kwiintlobo ezininzi zeeseli ze-tumor kwaye idlala indima ephambili kwi-tumor cell proliferation, umahluko, i-angiogenesis kunye nokusinda.
Ithagethi: FGFR
